Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the F...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Scott, Russell, O'Brien, Richard, Fulcher, Greg, Pardy, Chris, d'Emden, Michael, Tse, Dana, Taskinen, Marja-Riitta, Ehnholm, Christian, Keech, Anthony
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2009
Teme:
Cardiovascular and Metabolic Risk
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2646035/
https://ncbi.nlm.nih.gov/pubmed/18984774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc08-1543
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items